Skip to main content
. 2018 Aug 23;8:326. doi: 10.3389/fonc.2018.00326

Table 5.

Comparison of clinicopathological characteristics between gastric cancer patients with and without metabolic syndrome by CDS definition in males and females.

Features Male Female
MetS (n*, %) BMI (n, %) TG (n*, %) HDL-C (n, %) Hypertension (n*, %) Diabetes (n*, %) MetS (n*, %) BMI (n*, %) TG (n*, %) HDL-C (n*, %) Hypertension (n*, %) Diabetes (n*, %)
LOCATION
Proximal 54 (19.1) 95 (33.7) 42 (14.9) 40 (15.2) 80 (28.4) 76 (27.0) 2 (3.8) 19 (36.5) 6 (11.5) 10 (19.2) 8 (15.4) 10 (19.2)
Distal 78 (24.8) 82 (26.1) 68 (21.7) 48 (15.4) 78 (24.8) 66 (21.0) 20 (12.5) 46 (28.9) 36 (22.5) 36 (22.5) 46 (28.8) 36 (22.5)
x2 2.791 4.081 4.514 0.143 0.949 2.880 3.160 1.120 2.968 0.247 3.693 0.247
p 0.114 0.048 0.034 0.730 0.353 0.102 0.113 0.303 0.109 0.691 0.067 0.701
BORRMANN TYPE
I 30 (31.1) 39 (27.8) 10 (8.2) 12 (9.8) 44 (36.1) 38 (31.1) 4 (10.0) 17 (42.5) 10 (25.0) 12 (30.0) 8 (20.0) 6 (11.5)
II 36 (21.2) 55 (32.4) 30 (17.6) 26 (15.3) 38 (22.4) 38 (21.4) 6 (11.1) 15 (27.8) 14 (25.9) 12 (22.2) 12 (22.2) 16 (29.6)
III 60 (22.0) 75 (26.2) 62 (21.7) 46 (16.1) 70 (24.5) 60 (22.0) 12 (11.8) 31 (30.4) 14 (13.7) 22 (21.6) 32 (31.4) 20 (19.6)
IV 6 (33.3) 2 (11.1) 8 (44.4) 4 (22.2) 6 (33.3) 6 (33.3) 0 (0.0) 6 (37.5) 4 (25.0) 0 (0.0) 2 (12.5) 4 (25.0)
x2 2.048 5.054 18.657 3.584 8.264 5.980 1.051 2.759 4.598 6.066 4.220 3.421
p 0.632 0.168 < 0.001 0.310 0.041 0.113 0.789 0.445 0.204 0.108 0.469 0.331
HISTOLOGICAL GRADE
Well- 18 (11.8) 51 (33.6) 20 (13.2) 6 (3.9) 42 (27.6) 40 (26.3) 2 (6.7) 12 (40.0) 6 (20.0) 4 (13.3) 3 (20.0) 4 (13.3)
Poor- 114 (25.7) 120 (27.0) 90 (20.3) 82 (18.5) 116 (26.1) 102 (23.0) 20 (11.0) 59 (32.4) 36 (19.8) 42 (21.0) 24 (26.4) 42 (23.1)
x2 12.568 2.357 3.806 18.972 0.132 0.697 0.517 0.665 0.000 1.439 0.551 1.439
p < 0.001 0.146 0.053 < 0.001 0.750 0.404 0.747 0.412 1.000 0.339 0.651 0.339
T STAGE
T1 10 (10.6) 30 (31.9) 28 (29.8) 6 (6.4) 16 (17.0) 18 (19.1) 1 (3.3) 16 (44.4) 4 (11.1) 8 (22.2) 6 (16.7) 10 (27.8)
T2 18 (19.6) 28 (29.8) 16 (17.0) 10 (10.6) 22 (23.4) 22 (23.4) 3 (6.0) 10 (20.0) 8 (16.0) 4 (8.0) 14 (28.0) 10 (20.0)
T3 22 (26.5) 21 (24.4) 18 (20.9) 24 (27.9) 20 (23.3) 20 (23.3) 5 (31.3) 7 (43.8) 0 (0.0) 2 (12.5) 4 (25.0) 0 (0.0)
T4 82 (25.1) 95 (29.5) 48 (14.0) 48 (14.9) 100 (31.1) 82 (25.5) 13 (11.8) 33 (30.0) 30 (27.3) 32 (29.0) 30 (27.3) 26 (23.6)
x2 10.356 1.316 11.193 18.327 8.693 1.635 11.006 7.120 9.980 9.863 1.808 5.545
p 0.016 0.725 0.011 < 0.001 0.034 0.652 0.012 0.068 0.019 0.020 0.909 0.136
N STAGE
N0 46 (16.8) 83 (30.3) 60 (21.9) 38 (13.9) 64 (23.4) 54 (19.7) 6 (5.2) 21 (18.1) 20 (17.2) 22 (19.0) 28 (24.1) 24 (20.7)
N1 34 (31.5) 29 (26.9) 20 (18.5) 18 (16.7) 32 (29.6) 28 (25.9) 4 (12.5) 11 (34.4) 8 (25.0) 8 (25.0) 8 (25.0) 4 (12.5)
N2 32 (25.0) 40 (31.2) 18 (14.1) 20 (15.6) 36 (28.1) 38 (29.7) 4 (15.4) 10 (38.5) 2 (7.7) 4 (15.4) 8 (30.8) 6 (23.1)
N3 20 (23.3) 25 (29.1) 12 (14.0) 22 (14.0) 26 (30.2) 22 (25.6) 8 (21.1) 11 (28.9) 12 (31.6) 12 (31.6) 10 (26.3) 12 (31.6)
x2 10.686 0.629 4.857 0.606 2.720 5.392 8.891 7.271 6.741 3.509 0.511 3.876
p 0.014 0.890 0.175 0.895 0.437 0.145 0.031 0.064 0.081 0.320 0.916 0.275
TNM STAGE
I 20 (12.0) 41 (24.6) 42 (25.3) 8 (4.8) 36 (21.7) 36 (21.7) 2 (2.9) 29 (41.4) 10 (14.3) 12 (17.1) 16 (22.9) 14 (20.0)
II 40 (26.0) 36 (23.4) 28 (18.2) 44 (28.6) 34 (22.2) 30 (19.5) 6 (9.1) 16 (24.2) 14 (21.2) 12 (18.2) 16 (24.2) 16 (24.0)
III + IV 72 (26.1) 91 (33.0) 40 (14.5) 36 (13.0) 88 (28.9) 76 (27.5) 14 (18.4) 22 (28.9) 18 (23.7) 22 (28.9) 22 (28.9) 16 (21.1)
x2 13.611 5.977 8.057 37.023 7.626 4.114 9.661 5.357 2.144 3.686 0.788 0.389
p 0.001 0.049 0.018 < 0.001 0.022 0.128 0.008 0.069 0.232 0.158 0.674 0.832
*

n was positive patients number.

MetS, metabolic syndrome were identified by CDS; BMI ≥25.0 kg/m2; TG ≥1.70 mmol/L; HDL-C < 0.9 mmol/L for male, < 1.09 mmol/L for female; Hypertension: systolic BP ≥140, diastolic BP ≥90 mmHg or hypertension history; Diabetes ≥ 6.1 mmol/L or diabetes history.